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Treatment of hepatitis B virus-associated membranous nephropathy 
with adenine arabinoside and thymic extract. Previously we found that 
corticosteroid treatment in the hepatitis B virus (HBV)-associated 
membranous nephropathy (HBVMN) was not associated with a favor-
able outcome. To distinguish the differences of the HBV DNA in 
macrophage, T and B cells among HBVMN patients with or without 
corticosteroid treatment, serial studies at different time points were 
investigated. HBV DNA appeared as an "episomal" molecule as with 
3.2 kb in macrophage, T and B cells. This molecule disappeared after 12 
months among HBVMN patients without corticosteroid treatment. 
HBV DNA, by contrast, appeared as episomal form even three years 
later in T cells, with frequent proteinuria among HBVMN patients with 
corticosteroid treatment. This finding indicates that the use of cortico-
steroids leads to a potential risk of enhancing HBV viral replication in 
T cells. We studied 24 HBVMN patients who had previously received 
corticosteroid treatment and had persistent proteinuria, who were 
administered combination therapy with adenine arabinoside for two 
weeks and thymic extract (Thymostimulin) for six months to decrease 
urine protein loss and obtain seroconversion. These 24 patients had 
heavy (22 of 24, 91.6%) or mild (2 of 24, 8.4%) proteinuria prior to 
adenine arabinoside and thymostimulin treatment. All 24 patients 
demonstrated HBV DNA in mononuclear cells and simultaneously 
exhibited sera positive with HBsAg and HBeAg. In contrast, after 
treatment only one case (4.2%) had heavy and two cases (8.4%) mild 
proteinuria; HBV DNA was demonstrated in macrophage (4 of 24, 
16.7%), T cells (9 of 24, 37.5%), and B cells (6 of 24,25%) as well as 
serum (24 of 24, 100%) prior to treatment. The decreases to 16.7%, 
37.5%, 25% and 41.6% in the macrophage, T cell, B cell, and serum 
respectively, were statistically significant (P < 0.01) in each instance. In 
addition, six cases with complete remission of proteinuria changed their 
hepatitis B markers. Four cases (16.7%) changed from HBe (+)/anti-
HBe (-) to HBe (-)/anti-HBe (-). These results suggest that combi-
nation therapy of adenine arabinoside and Thymostimulin in HBVMN 
patients is more effective in the improvement of proteinuria than 
corticosteroid treatment. 
Human infection with hepatitis B virus (HBV) can lead to 
acute and chronic hepatitis, liver cirrhosis and hepatocellular 
carcinoma [1-3]. Combes et al also described the association of 
HBV with membranous nephropathy (HBVMN) [4]. Current 
evidence suggests that HBV itself is not cytopathic and that 
liver cell damage is limited to the host immune responses 
directed at viral and/or self-antigens expressed on the mem-
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brane of infected hepatocytes [5, 6]. Recent reports also indi-
cate that HBV DNA may be detected in peripheral blood 
leukocytes of patients with HBV infection [7, 8]. If HBV does 
infect human leukocytes, such infection may interfere with the 
immunological functions of the mononuclear cells, thus playing 
an important role in the pathogenesis of HBV-induced liver or 
kidney diseases. Most of the studies confirming that HBV DNA 
is detectable in human T cells, however, were carried out on 
chronic HBV liver disease or HBV asymptomatic carriers [7, 
8]. Only one study previously has demonstrated the presence of 
HBV DNA in macrophages [9]. 
The HBVMN is transmitted horizontally [10, 11]. The mac-
rophage acts as the first line defense mechanism and provides 
antigen recognition. HBV DNA, therefore should be detectable 
in macrophage at the early stage of HBV infection among 
HBVMN patients. Direct detection of HBV DNA in macro-
phages, T and B cells, and serum using the molecular hybrid-
ization test has been proven to be a sensitive and reliable 
method in determining viral replication and infectivity of HB-
sAg carriers [12-14]. On the other hand, correlation between 
hepatitis B e antigen (HBeAg) and antibody (anti-HBe) and 
HBV DNA in HBVMN has not been well documented. The 
specific aim of this longitudinal study, therefore, was to inves-
tigate the serial changes of HBV DNA in macrophage, T, B 
cells, serum and HBV serological markers (HBsAg, HBeAg) 
and their association with proteinuria involved in HBVMN 
patients before and after treatment. 
Methods 
Patient selection 
Twenty-four children younger than 12 years of age diagnosed 
with HBVMN from January 1986 to November 1987 were 
recruited for the study and referred to the Department of 
Pediatrics, Veterans General Hospital for renal biopsy. Inclu-
sion criteria consisted of treatment of prednisolone 2 mg per kg 
daily for more than eight weeks and persistent nephrotic 
syndrome or heavy proteinuria. In each HBVMN case, a 
kidney biopsy specimen was collected and divided into three 
portions for light, immunofluorescence, and electron micro-
scopic studies [10, 11]. HBsAg was stained with polyclonal 
rabbit anti-HBs (Dako Corporation, Santa Barbara, California, 
USA) and monoclonal mouse anti-HBs IgG antisera by indirect 
immunofluorescent technique [10, 11]. For the immunofluores-
cent demonstration of HBcAg in tissues, 4 JLm thick cryostat 
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was first stained with 1: 1600 dilution of rabbit anti-HBc anti-
body (Dako Corp), and HBe was stained with FITC-conjugated 
anti-HBe IgG monoclonal antibody [15]. For negative control, 
anti-HBe, anti-HBs and anti-HBc antibodies were replaced by 
phosphate buffered saline (PBS). Ten cases of membranous 
nephropathy (MN) in adult patients with no detectable serum 
HBsAg (9 cases) or positive serum HBsAg (I case) were also 
examined. A negative result was obtained in all. 
The criteria for diagnosis of HBVMN were: (I) renal biopsy 
showed membranous glomerular thickening in the light micros-
copy, and immunofluorescent staining demonstrated at least 
one of the diffuse granular capillary membranous deposits 
among HBsAg, HBcAg and HBeAg in immunohistology; (2) 
serum HBsAg positive; (3) abnormal urinalysis; (4) there were 
no other types of viral infection such as cytomegalovirus or 
Epstein-Barr virus. The criteria of nephrotic syndrome (NS) 
include: (1) heavy proteinuria greater than 40 mg/M2/hr deter-
mined quantitatively on a 24-hour overnight urine collection; (2) 
hypoalbuminemia less than 2.5 g/dl; (3) puffy face, generalized 
edema. Any patient with only the first criterion was defined as 
"heavy proteinuria". Proteinuria between 4 mg/M2/hr and 40 
mg/M2/hr was defined as "mild proteinuria". Less than 4 
mg/M2/hr was defined as "free of proteinuria". 
After renal biopsy confirmed HBVMN, these HBVMN pa-
tients received one course of intravenous infusion of 15 mg per 
kg body weight daily of adenine arabinoside (Ara-A) for two 
weeks. They then received thymic extract (Thymostimulin, 
TP-l, Instituto Farmacologico Serono, Rome, Italy) 2 mg per kg 
body weight intramuscular daily for six months. If a patient had 
seroconversion to HBsAg (-)/HBe (-) then Thymostimulin 
therapy was stopped. 
Control subjects 
The control groups included 10 age- and sex-matched HBsAg 
(-)/HBe (-) healthy controls. 
Serologic tests 
Sera separated soon after venesection were stored at -70°C. 
Serum HBsAg, anti-HBs, HBeAg, anti-HBe, and anti-HBc 
were measured by radioimmunoassay (Abbott Laboratories, 
Abbot Park, Illinois, USA). 
Separation of macrophage, T and B cells 
Heparinized peripheral blood samples were obtained monthly 
from the HBVMN patients. The blood mononuclear cells 
(MNC) were isolated by the Ficoll-Hypaque gradient density 
method [10,16]. Fifteen milliliters ofMNC suspension were put 
into a 100 x 15 mm plastic petri dish (Flacon plastics) and 
incubated in a humidified, 37°C, 5% CO2 incubator for 50 
minutes. The adherent cells were harvested by rubber "police-
man", washed, and then the whole process was repeated three 
times. The non-adherent cells were separated by E-rosettes 
technique and flow cytometry (Coulter EPICS C, Hialeah, 
Florida, USA). The T cells forming E-rosettes were pelle ted on 
the bottom and were separated with cold distilled water. The B 
cells were separated with Ficoll-Hypaque gradient and centri-
fuged at 400 g at room temperature for 30 minutes. Then the 
interface layer was aspirated and passed through flow cytome-
try. 
To verify the effectiveness of the separation procedure, T 
cells, B cells and macrophages were incubated for 30 minutes at 
4°C with phycoerythrin-labeled monoclonal antibodies to CD3 
(Ortho Pharmaceuticals, Raritan, New Jersey, USA), B7 (Or-
tho) and Mo (Coulter Immunology). T cells, B cells and 
macrophages bound to each monoclonal antibody were sorted 
with a fluorescence-activated cell sorter (Coulter EPICS C). 
U sing this sorting technique, the T cell suspension was almost 
100% CD3 positive cells and the B cell suspension about 100% 
B7-positive cells. The final cell suspension contained about 
100% M02 and 9S% peroxidase-positive cells. 
DNA extraction 
Macrophage, T and B cells were washed at least three times 
with phosphate-buffered saline (PBS; 150 mM NaCl, 10 mM 
phosphate, pH 7.2) to remove HBV which might be present in 
the serum. The supernatant from the last wash was kept to use 
as control in hybridization experiments. The washed cells were 
then digested overnight with 500 J-Lg/ml of self-digested protease 
in 10 mM Tris, pH S.O, 150 mM NaCI, 10 mM EDTA, and 0.5% 
sodium dodecyl sulfate (SDS) at 37°C. The mixture was then 
extracted twice with equilibrated phenol and once with phenol! 
chloroform/isoamyl-alcohol mixture (25:24:1). RNase A was 
added to 100 J-Lg/ml, incubated at 37°C for one hour, and treated 
with protease at 500 J-Lg/ml at 37°C for one hour. DNA was 
precipitated with two volumes of cold ethanol after further 
phenol extraction. The DNA pellet obtained after centrifugation 
was dissolved in 10.0 mM Tris, pH S.O, and 10 mM EDTA. 
Concentration and quality of each DNA preparation were 
determined by measurements of A260 and A280 [17]. 
Hybridization 
Thirty microliters of serum were first transferred to a fresh 
tube for detection by slot hybridization of HBV DNA in sera 
[13]. SDS and EDTA were added in 5 J-LI volume each to final 
concentrations of 0.5% and 5 mM, respectively; 5 J-Llofprotein-
ase K (1.2 mg/ml) were added and the mixture was incubated at 
56°C for four hours. A single volume of 2 M NaCI and two 
volumes of 1 M NaOH were then added. The solution was 
loaded onto nitrocellulose filters (Schleicher & Schuell, BAS5, 
0.45 J-Lm, Dassel, Germany) using a 96-well manifold designed 
for multiple-sample dot hybridization (Schleicher & Schuell, 
SRC 072/0, minifold II) under mild suction after standing at 
room temperature for 20 minutes. Four volumes of neutraliza-
tion solution (0.5 M Tris, pH 7.4, 3 M NaCl) were then used to 
wash the filter. The filter was baked at SO°C under vacuum and 
used for hybridization experiments. This method is able to 
detect less than 1 pg of HBV DNA. 
Twenty micrograms of EcoRI-digested or undigested leuko-
cyte DNA were electrophoresed in O.S% agarose gel for South-
ern blot analysis of DNA samples. DNA was denatured by 
soaking the gel in several volumes of 1.5 M NaCI and 0.5 M 
NaOH for one hour at room temperature with constant shaking, 
followed by neutralization in 1 M Tris (pH S.O) and 1.5 M NaCI 
for one hour at room temperature. Blotting of electrophoresed 
DNA samples onto nitrocellulose filter was carried out as 
described [IS] for 36 hours. The nitrocellulose filter was then 
baked for two hours at SO°C under vacuum. The filters were 
soaked in 6x SSC (1 x SSC is 150 mM NaCl, 15 mM Naz 
citrate), 0.5% SDS, 100 J-Lg/ml salmon sperm DNA (Sheared and 
denatured), 10 mM EDTA, and 5x Denhardt's solution (Ix 
Lin and Lo: MBV DNA in cells of HBVMN patients 303 
Denhardt's solution is 0.02% Ficoll , 0.02% polyvinylpyroli-
done , 0.02% bovine serum albumin) at 68°C for six hours for 
prehybridization. The HBV probe was prepared from an HBV 
plasmid clone pTWLl [19]. EcoRI digestion ofpTWLl released 
a 3.2 kb fragment, which was then freed from its cloning vector 
(PUC8) by isolation from low melting temperature agarose gel. 
The HBV fragment was labelled by nick-translation procedure 
to specific activity of 2 to 5 X 108 cpmJ JLg DNA using 
(a-32P]dCTP (New England Nuclear, Boston, Massachusetts, 
USA). Alkali-denatured 32P-Iabeled HBV DNA probe was 
added to the prehybridization solution after prehybridization. 
At least a tenfold excess of denatured and unlabeled pUC8 
DNA was also added to the hybridization mixture in order to 
eliminate spurious hybridization signals due to possible minor 
contamination of the cloning vector (pUC8). The hybridization 
was carried out at 68°C for 36 hours. The filters were washed 
twice in 2x SSC, 0.1% SDS for 15 minutes each at room 
temperature , twice in 1 x SSC, 0.1% SDS at 65°C for one hour 
each after hybridization, and finally in two changes of 0.5 x 
SSC, 0.1 % SDS, also at 65°C for one hour each. The filters were 
dried and autoradiographed with x-ray film (Eastman Kodak, 
X-MOATAR film , Rochester, New York, USA) at -70°C with 
two sheets of intensifying screens (KYOKKO) for various time 
intervals. 
Statistics 
Data are presented as mean ± so. Comparisons were made 
using Chi-Square test and Student's t-test for paired data. 
Results 
HBV DNA in macrophage, T cells , and B cells among 
HBVMN patients with or without corticosteroid treatment 
Macrophage, T cell and B cell cellular DNA samples were 
analyzed by southern blot hybridization using EcoRI to deter-
mine the form ofHBV DNA molecules. HBV DNA appeared as 
3.2 kb episomal molecules only in macrophage, T and B cells 
before the first six months after onset of disease (Fig. lA) for 
those HBVMN patients who had not received corticosteroid 
treatment. When HBV DNA was digested with BanHI, 1.4 kb 
molecules appeared. Comparison of HindIII digested and undi-
gested DNA revealed that the position of the HBV band had not 
changed after HindIII digestion, indicating that the HBV DNA 
molecules of the HBVMN patients did not contain a HindIIl 
site as reported by others [17]. Six months later, the 3.2 kb 
HBV DNA in macrophage had disappeared. The 3.2 kb HBV 
DNA persistently existed, however, either in the T or B cells. 
The cellular HBV DNA disappeared 12 months later. HBV 
DNA appeared by contrast as episomal form (3.2 kb) even three 
years later in T cells (Fig. lB) in patients with persistent 
proteinuria who had received corticosteroid treatment. These 
results indicate that the use of corticosteroid may lead to a 
potential risk of enhancing HBV viral replication in T cells. 
Cellular HBV DNA profile in macrophages, T cells and B 
cells among 24 HBVMN patients 
Cellular HBV DNA profiles in macrophages, T cells and B 
cells among the 24 HBVMN patients who had previously 
received corticosteroid treatment before the combination treat-
ment of adenine arabinoside and Thymostimulin, using slot-blot 
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Fig. 1. Serial HBV DNA in macrophage, T and B cells was observed in 
two cases (A. without steroid treatment; B. with steroid treatment) . 
hybridization are shown in Figure 2. Fifteen cases (62.5%), 23 
cases (95.8%) and 21 cases (87.5%) demonstrated HBV DNA in 
macrophages, T cells and B celis , respectively. All cases at this 
time had HBV DNA in both sera and mononuclear cells 
simultaneously as shown in Table 1. 
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Fig. 2. Study of cellular HBV DNA in 24 cases using slot-blot hybrid-
ization in the pre-treatment. 
Evaluation of adenine arabinoside and Thymostimijlin 
treatments by serial detection of HBV markers and 
proteinuria at different time .intervals 
All caSes (lOO%) had cellular HBV . DNA in sera and in 
mononuclear cells (either in the macrophage or T and B cells) 
with 100% seropositivity rates of both HBsAg (+ )/HBe (+) 
simultaneously, and before adenine arabinoside and Thymo-
stimulth treatments. A review of the clinical manifestations 
demonstrated that 22 cases (91.6%) had heavy proteinuria and 
two clises (8.4%) mild proteinuria during the pre-treatment time 
(Table 1). By contrast, two cases with mild proteinuria recov-
ered free of proteinuria, and all 22 cases of heavy proteinuria 
had decreased their urinary protein losses with only two cases 
still in the mild proteinuria state (Table 1). Twelve cases (50%), 
20 c\lses (83.3%), 14 cases (58.3%) and 19 cases (79.2%) 
demonstrated HBV DNA in macrophages, T cells and B cells 
and plasma, respectively. Only one case, however, had HBeAg 
serocoriversion with HBe (-)/anti-HBe (+), and one case only 
presented anti-HBe antibody in HBe (+ )/anti-HBe (+) status. 
Only one case still bad urinary protein loss more than 40 mg per 
M2 per day, and ,two cases had mild proteinuria in the total of 22 
cases of heavy proteinuria before treatment (Table 1), at the end 
of SIX months after treatment. The other cases attained remis-
sion. There were only four cases (16.7%) in macrophages; nine 
cases (37.5%) in T cells, and six cases (25%) in B cells with 
cellular imv DNA. Ten cases (41.6%), however, were still 
positive with HBV DNA in sera as shown in Table 1. Therefore 
HBV DNA was detected more frequently in serum than in 
mononuclear cells. These striking decreases of cellular DNA 
from pre-treatment (62.5%, 95.8%, 87.5%, ana iOO%, respec-
tively) to post-treatment (16.7%,37.5%,25.0%, and 41.6%) in 
macrophages, T cells, B cells, and plasma HBV DNA were 
statistically significant (P < 0.01) (Table 1). Serologically, six 
months after treatment, four cases (16.7%) changed their hep-
atitis B markers from HBsAg (+ )IHBsAb (-), HBe (+ )/anti-
HBe (-) to HBsAg (+ )/HBsAb (-j , HBe (+ )/anti-HBe (+), 
two cases (8.4%) from HBsAg (+ )/HBsAb (-), HBe (+ )/anti-
HBe (-) to HBsAg (+ )IHBsAb (-), HBe (-)/anti-HBe (+) and 
another two cases (8.4%) from HBsAg (+)IHBsAb (-), HBe 
(+ )lanti-HBe (-) to HBsAg (-)/HBsAb (-), HBe {-)/anti-HBe 
(+) and HBsAg (-)/HBsAb (+), HBe (-)/anti-HBe (+) , re-
spectively; all had completeremission of proteinuria. The last 
heavy proteinuria case still progressively improved, becoming 
mild proteinuria at second month and then complete remission 
at eleventh month, after discontinuation of adenine arabinoside 
and Thymostimlilin treatment. The other two mild proteinuria 
cases also attained complete remission at nine and ten months, 
respectively. During the second six follow-up months, one case 
changed from HBsAg (+ )IHBsAb (-), HBe (-)/anti-HBe (+) 
to HBs (-)/anti-HBs (-) , HBe (-)/anti-HBe (+) , and another 
one from HBsAg (+ )IHBsAb (-'-), HBe (+ )/anti-HBe (-) to 
HBsAg (+ )IHBsAb (- ), HBe (+ )/anti-HBe (+). 
Correlation among HBV DNA, HBsAg, HBe markers and 
proteinuria 
There were 22 cases (91.6%) in the heavy proteinuria state 
(>40 mg!M2/hr) who were positive for both HBe (+ )/ariti-HBe 
(-) and cellular/serum HBV DNA (+) as shown in Table 2. On 
the other hand, either in the HBe (-)/anti-HBe (-) or HBe 
(- )/anti-HBe (+) status , only one case (6.25%) was positive for 
cellular/serum HBV DNA and had heavy proteinuria. The 
difference between these two groups was statistically significant 
(P < 0.(01) . This result also confirms our previous data that 
most of the cases had disappearance of heavy proteinuria and 
then attained HBe serocoriversion [11]. Cellular/serum HBV 
DNA and proteinuria in contrast did not always disappear in the 
HBe (-)/HBsAg (+) status either with HBsAb (-) or HBsAb 
(+). 
Discussion 
In the present study we demonstrated that HBV DNA 
appeared as episomal molecule only with 3.2 kb in macro-
phages, T cells and B cells, but that this molecule disappeared 
after] 2 months amohg HBVMN patients without corticosteroid 
treatment. By contrast, HBVMN appeared as episomal form tip 
to three years later in T cells with frequent proteinuria among 
HBVMN patients with corticosteroid treatment, indicating that 
corticosteroids has a potential risk of enhancing HBV replica-
tion in mononuclear cells. 
HBV DNA in mononuclear cells in the present study was 
detected by Southern blot analysis of cellular DNA extracted 
from extensively washed macrophages, T cells and B cells. The 
cells were washed at least three times in order to rule out the 
possibility of serum contamination of mononuclear cells. The 
supernatant from the last wash showed no detectable signals by 
dot hybridization. Furthermore, the HBV DNA probe prepara-
tions, when tested against pUC8 DNA on filter, showed no 
hybridization signals, indicating that the probe preparations 
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Table 1. Serial changes of hepatitis B markers , HBV DNA and proteinuria before and after Ara-A and TP-I treatment 
Before After Ara-A & TP-I 
Ara-A & TP-I 3rd Month 6th Month 9th Month 12th Month 
Proteinuria 
>40 mg/M2/hr 22 (91.6%)a.b.c 2 (8.3%)b.d I (4.2%)c.f 0 0 
4-40 mg/M2/hr 2 (8.4%)" 3 (l2.s%)e 2 (8.4%)g 2 (8.4%) 0 
< 4 mg/M2/hr 0 19 (79. 2%)d.e 21 (87.S%jLg 22 (91 .6%) 24 (100%) 
HBV DNA (+) 
in Monoclonal antibodies IS (62.5%) 12 (SO.O%) 4 (16.7%) 0 0 
T cell 23 (9S .8% ) 20 (83.3%) 9 (37.S% ) 6 3 (12.5%) 
B cell 21 (87.5%) 14 (58.3%) 6 (25.0%) 4 2 (8.4%) 
in plasma 24 (100%) 19 (79.2%) 10 (41.6%) 7 5 (20.8%) 
HBsAg(+) 24 (100%) 24 (100%) 22 (91 .6%) 22 (91.6%) 21 (87.5%) 
eAg( + )eAb( - ) 24 (100%) 22 (91 .6%)h 16 (66.6%)ij IS (62.5%) 13 (54 .2%) 
eAg( + )eAb( + ) 0 1 (4.2%)h 4 (l6.7%)i 5 (20.8%) 6 (25.0%) 
eAg( - )eAb( + ) 0 I (4.2%t 2 (8.4%Y 2 (8.4%) 2 (8.3%) 
HBsAg( - )HBe( - ) 0 0 
HBsAb(-) 0 0 
HBsAb(+) 0 0 
.-j P < 0.01 
Table 2. Correlation among macrophage, T , B cell and serum 
HBVDNA, HBe, HBsAg markers and proteinuria in HBVMN 
patients 
HBsAg (+) HBsAg (- ) 
eAg (+) eAg(-) eAg (-) HBsAb HBsAb 
eAb (-) eAb (-) eAb (+) (-) (+) 
No. of cases 24 16 16 2 4 
HBVDNA (+) 
in Monoclonal 15 0 0 0 0 
antibodies 
T cell 23 3 0 0 0 
B cell 21 I 0 0 0 
in plasma 24 8 2 0 0 
Proteinuria 
>40 mg/M2/hr 22 I I 0 0 
4-40 mg/M2/hr 2 6 2 0 0 
< 4 mg/M2/hr 0 9 13 2 4 
were free from. spurious DNA sequences of bacterial origin. 
With EcoRI digestion , only 3.2 kb HBV DNA was' detected in 
macrophages, T cells and B cells before six months post-onset 
of disease. HindIII sites were not observed in the HBV DNA. 
These results indicate that the HBV DNA does not integrate 
into the genomic DNA of the host mononuclear cells but is 
present in a free replicating form. 
The study of Yoffe et al also found that replicating forms of 
the HBV genome were present primarily in monocytes. Low 
levels of hybridization also were detected in B cells, whereas 
the T cell fraction appeared to be devoid of these replicating 
forms [9] . Our results demonstrated cellular HBV DNA not 
only in the macrophages and B cells, but also in the T cells. The 
different results may be due to the types of patients or the study 
models. Yoffe's patients had liver disease, and our cases 
demonstrated predominantly renal involvement. Yoffe only did 
one-time blood samples, while we did serial studies . The 
presence of HBV DNA in macrophages during the early stage 
of disease course and in t or B cells in HBVMN patients 
suggests that HBV is involved in immune regulation [10]. 
The study of Lai et al also demonstrated an increase of 
2 (8.4%) 2 (8.4%) 3 (12.5%) 
1 (4.2%) I (4.2%) 2 (8.4%) 
1(4.2%) 1(4.2%) 1(4.2%) 
plasma HBV DNA concentration in HBVMN patients treated 
with corticosteroids [20] ; Patients had a persistent elevation of 
HBeAg in their serum after corticosteroid withdrawal [20]. 
Therefore, the use of corticosteroids could lead to a potential 
risk of enhancing virai replication. 
HBVMN is definitely not a benign disease. Some HBVMN 
patients have progressed into chronic renal failure [11]. It is 
necessary and important to evaluate the mechanism of HB-
VMN and to search for a satisfactory treatment in an area of 
high prevalence of HBV infection like Taiwan. It is notable that 
some of the patients with HBV infection have HBVMN while 
others do not. We hypothesize that: 1) patients with HBVMN 
probably have a defect in immune regulatory function and 
cannot produce high affinity antibodies to neutralize antigen 
present in the body ; 2) a defect in the reticuloenthothelial 
system (RES) to clean circulating immune complexes may also 
be present in these patients. This disease in the past was treated 
by immune inhibitory drugs, which probably further inhibited 
the production of high affinity antibodies. Thymic factor was 
also used successfully in mainland China to treat patients who 
had heavy proteinuria unresponsive to steroid therapy. The 
possible mechanism of pharmacologic effect of thymic factor is 
promotion of T cell function through enhancing the production 
of cytokines [21], that is, immune modulation. To decrease 
urinary protein loss and obtain seroconversion in these pa-
tients , adenine arabinoside [22, 23], thymic factor [24] and 
interferon [25] have been used. None of these, however, had a 
satisfactory result. Therefore, we planned to combine adenine 
arabinoside with thymic factor (Thymostimulin) to treat chil-
dren with HBVMN who had failed steroid treatment but still 
had persistent heavy proteinuria. 
Heavy proteinuria in 19 cases (79.2%) from our presented 
data disappeared within three months after starting this proto-
col. Microscopic hematuria, however, persisted in all cases. 
Proteinuria reappeared in some cases during upper respiratory 
tract infection. Eight cases had hepatitis marker change. Two 
cases had HBe seroconversion with HBs seroconversion. An-
other two cases had HBsAg (+ )/HBe ( + ) attained seroconver-
sion and disappearance of both HBsAg and HBeAg. Therefore, 
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this treatment protocol is more effective in the improvement of 
proteinuria. 
In conclusion, first, our results do not support the earlier 
notion suggested by Cadrobbi et al [26] that corticosteroids 
given at the onset of nephrotic syndrome are associated with a 
favorable outcome of the infection cir the related renal disease 
[20] . Use of corticosteroids in HBVMN patients should be 
avoided. Corticosteroid treatment not only runs the risk of 
enhancing viral replication but also may result in producing 
more low-affinity antibodies and/or decreasing activity of the 
reticuloendothelial system, thus making the body fail to clear 
the invading antigen. It then causes more deposition of immune 
complexes in the basement membrane of the capillary wall of 
the glomerulus. Second, combination therapy with adenine 
arabinoside and Thymostimulin is more effective in the im-
provement of proteinuria. Further research is necessary to 
determine methods of providing hepatitis B seroconversion. 
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